Impact of Rifabutin on the Pharmacokinetics of Elexacaftor/Tezacaftor/Ivacaftor

PHASE4CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

May 9, 2022

Primary Completion Date

May 30, 2024

Study Completion Date

May 30, 2024

Conditions
Drug Drug Interaction
Interventions
DRUG

Trikafta [orange tablet containing ELX 100mg, TEZ 50mg, and IVA 75mg]

Subjects will receive a single dose of trikafta (orange tablet) on day 1 of period 1 and on day 15 of period 2.

DRUG

Rifabutin 300mg

After washout period greater or equal to 2 days, subjects will receive 300 mg/d of rifabutin on days 1 through 17 of period 2.

Trial Locations (1)

90033

University of Southern California, Los Angeles

All Listed Sponsors
lead

University of Southern California

OTHER